#1 Clinical Trials Search in Europe

Anti-(Misfolded Human Superoxide Dismutase 1) Human Igg1M3 Monoclonal Antibody

A groundbreaking clinical trial is underway to evaluate the potential of AP-101, an innovative antibody treatment for Amyotrophic Lateral Sclerosis (ALS). This Phase 2a study aims to assess the safety, tolerability, and effectiveness of AP-101 in patients with both familial and sporadic forms of ALS. The trial involves multiple intravenous doses over a 6-month period, with the possibility of an open-label extension. Researchers are hopeful that this new approach could offer new possibilities for ALS patients, a condition for which treatment options are currently limited.

Table of Contents

What is AP-101?

AP-101 is a new medication being studied for the treatment of Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease. It is a type of drug called a monoclonal antibody, which is a laboratory-made protein that can target specific molecules in the body[1].

This drug is also known by several other names, including:

  • Alpha-miSOD1
  • Recombinant human IgG1m3 antibody directed against misfolded human SOD1
  • Human IgG1m3 antibody directed against misfolded human superoxide dismutase 1

AP-101 is classified as a biological or biotechnological product, which means it is derived from living organisms rather than being chemically synthesized[1].

How Does AP-101 Work?

AP-101 is designed to target a specific protein in the body called superoxide dismutase 1 (SOD1). In some people with ALS, especially those with a familial form of the disease, the SOD1 protein can become misfolded, leading to the death of motor neurons[1].

The goal of AP-101 is to bind to these misfolded SOD1 proteins and potentially slow down or stop their harmful effects on motor neurons. By doing so, it may help to slow the progression of ALS in patients with this specific form of the disease[1].

Current Research on AP-101

AP-101 is currently being studied in a Phase 2a clinical trial. This is an early stage of research that aims to evaluate the safety, tolerability, and early signs of effectiveness of the drug in people with ALS[1].

The study is designed as a multicenter, randomized, double-blind, placebo-controlled study. This means that:

  • It is being conducted at multiple hospitals or research centers
  • Participants are randomly assigned to receive either AP-101 or a placebo (a substance with no active ingredients)
  • Neither the participants nor the researchers know who is receiving the actual drug or the placebo during the study

The study consists of two phases:

  1. A double-blind phase lasting 6 months
  2. An open-label extension phase where all participants receive AP-101

Who Can Participate in the AP-101 Study?

The study is looking for participants who meet specific criteria, including:

  • Adults aged 18 years or older
  • Diagnosed with either familial or sporadic ALS
  • Onset of ALS symptoms (weakness) within the past 24 months
  • For familial ALS patients, a confirmed pathogenic SOD1 mutation
  • Ability to breathe on their own (with some restrictions on ventilator use)

There are also several factors that would exclude someone from participating, such as:

  • Pregnancy or nursing
  • Recent participation in other clinical trials
  • Severe psychiatric illness
  • Diagnosis of another neurodegenerative disease (e.g., Parkinson’s or Alzheimer’s)

It’s important to note that these are just some of the criteria, and the full list is more extensive[1].

Study Objectives and Endpoints

The main objectives of the study are:

  1. To determine the safety and tolerability of AP-101 when given intravenously (through a vein) over 6 months
  2. To study how AP-101 moves through the body (pharmacokinetics)
  3. To see if AP-101 can reach the fluid around the brain and spinal cord (cerebrospinal fluid or CSF)
  4. To measure the effects of AP-101 on certain proteins in the blood and CSF that are associated with nerve damage in ALS

The researchers will be looking at several key outcomes (endpoints) to assess these objectives, including:

  • The occurrence of side effects
  • Changes in vital signs, laboratory tests, and physical examinations
  • Levels of AP-101 in the blood and CSF
  • Changes in levels of proteins associated with nerve damage (neurofilaments) in the blood and CSF

Potential Benefits and Considerations

While AP-101 shows promise, it’s important to remember that it is still in the early stages of research. The potential benefits and risks are not yet fully known. Some considerations include:

  • AP-101 is specifically designed for people with ALS, particularly those with SOD1 mutations
  • The drug is given intravenously, which means regular hospital visits for infusions
  • As with any new treatment, there may be unknown side effects
  • Participation in the study involves multiple medical tests and procedures, including lumbar punctures to collect CSF

It’s crucial for anyone considering participation in this or any clinical trial to discuss the potential risks and benefits with their healthcare provider[1].

Aspect Details
Study Type Phase 2a, multicenter, randomized, double-blind, placebo-controlled
Drug Name AP-101 (Anti-misfolded human superoxide dismutase 1 human IgG1m3 monoclonal antibody)
Condition Amyotrophic Lateral Sclerosis (ALS) – both familial and sporadic forms
Primary Objectives Evaluate safety and tolerability of AP-101 after multiple IV doses
Secondary Objectives Assess pharmacokinetics, CSF penetration, effects on biomarkers (pNfH and NfL)
Key Inclusion Criteria Adults (18+) with ALS diagnosis, symptom onset within 24 months, SVC ≥50% of predicted
Key Exclusion Criteria Recent exposure to SOD1-targeting treatments, stem cell therapy, severe psychiatric illness
Treatment Duration 6 months (double-blind phase) with possible open-label extension
Administration Multiple intravenous (IV) doses

FAQ

  • What is AP-101 and how does it work? AP-101 is an antibody treatment specifically designed to target misfolded human superoxide dismutase 1 (SOD1), a protein associated with some forms of ALS. It works by binding to and potentially neutralizing the harmful effects of this misfolded protein, which is believed to contribute to the progression of ALS.
  • Who is eligible to participate in this clinical trial? The trial is open to adults (18 years or older) with a diagnosis of familial or sporadic ALS, with symptom onset within the past 24 months. Participants must meet specific criteria, including having a slow vital capacity (SVC) of 50% or higher of predicted values and not requiring extensive respiratory support.
  • How is the medication administered in this trial? AP-101 is administered through intravenous (IV) infusion. Participants will receive multiple doses over a 6-month period during the double-blind phase of the study. There is also an open-label extension phase where all participants may receive the active treatment.
  • What are the main objectives of this clinical trial? The primary objective is to determine the safety and tolerability of AP-101 after multiple IV doses. Secondary objectives include evaluating the pharmacokinetics (how the drug moves through the body), assessing its penetration into the cerebrospinal fluid, and measuring its effects on certain biomarkers associated with ALS progression.
  • Are there any restrictions for participants during the trial? Yes, there are several restrictions. Participants must adhere to contraception requirements, cannot initiate new ALS treatments during the double-blind phase, and must not have participated in other clinical trials within a specific timeframe before the study. Additionally, they cannot have undergone stem cell therapy or have certain other medical conditions.

Ongoing Clinical Trials on Anti-(Misfolded Human Superoxide Dismutase 1) Human Igg1M3 Monoclonal Antibody

  • Study on the Safety and Effects of AP-101 for Patients with Amyotrophic Lateral Sclerosis (ALS)

    Not recruiting

    1
    Investigated diseases:
    Investigated drugs:
    Sweden

Glossary

  • Amyotrophic Lateral Sclerosis (ALS): A progressive neurological disease that causes the death of neurons controlling voluntary muscles, leading to muscle weakness and atrophy.
  • Familial ALS (fALS): A form of ALS that runs in families and is caused by genetic mutations, such as those in the SOD1 gene.
  • Sporadic ALS (sALS): The most common form of ALS, occurring in individuals with no family history of the disease.
  • Superoxide Dismutase 1 (SOD1): An enzyme that helps protect cells from oxidative stress. Mutations in the SOD1 gene are associated with some cases of familial ALS.
  • Monoclonal Antibody: A type of protein made in the laboratory that can bind to specific substances in the body, used in the treatment of various diseases.
  • Intravenous (IV): A method of administering medication directly into a vein.
  • Pharmacokinetics (PK): The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.
  • Cerebrospinal Fluid (CSF): A clear, colorless fluid that surrounds the brain and spinal cord, protecting them and providing nutrients.
  • Neurofilament: Proteins found in neurons that can be measured in blood or CSF as markers of neuronal damage or degeneration.
  • Slow Vital Capacity (SVC): A measure of lung function, specifically the amount of air that can be slowly exhaled after taking a deep breath.
  • El Escorial Criteria: A set of diagnostic criteria used to classify the likelihood of ALS in a patient based on clinical and laboratory findings.
  • Open-label Extension (OLE): A phase of a clinical trial where all participants receive the active treatment, often following a double-blind phase.
  • Biomarker: A measurable indicator of a biological state or condition, often used to track disease progression or treatment effects.

References

  1. http://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-ap-101-for-patients-with-amyotrophic-lateral-sclerosis-als/